Literature DB >> 19164600

A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation.

Xiufen Zheng1, Costin Vladau, Xusheng Zhang, Motohiko Suzuki, Thomas E Ichim, Zhu-Xu Zhang, Mu Li, Ewa Carrier, Bertha Garcia, Anthony M Jevnikar, Wei-Ping Min.   

Abstract

Translation of small interfering RNA (siRNA)-based approaches into practical therapeutics is limited because of lack of an effective and cell-specific delivery system. Herein, we present a new method of selectively delivering siRNA to dendritic cells (DCs) in vivo using CD40 siRNA-containing immunoliposomes (siILs) that were decorated with DC-specific DEC-205 mAb. Administration of CD40 siILs resulted in DC-specific cell targeting in vitro and in vivo. On treatment with CD40 siILs, the expression of CD40 in DCs, as well allostimulatory activity was inhibited. In vivo administration resulted in selective siRNA uptake into immune organs and functional immune modulation as assessed using a model antigen. In conclusion, this is the first demonstration of DC-specific siRNA delivery and gene silencing in vivo, which highlights the potential of DC-mediated immune modulation and the feasibility of siRNA-based clinical therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164600     DOI: 10.1182/blood-2008-04-151191

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  microRNAs in the regulation of dendritic cell functions in inflammation and atherosclerosis.

Authors:  Martin Busch; Alma Zernecke
Journal:  J Mol Med (Berl)       Date:  2012-02-04       Impact factor: 4.599

Review 2.  Dendritic cell control of tolerogenic responses.

Authors:  Santhakumar Manicassamy; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

3.  Nanosac, a Noncationic and Soft Polyphenol Nanocapsule, Enables Systemic Delivery of siRNA to Solid Tumors.

Authors:  Hyungjun Kim; Simseok A Yuk; Alexandra M Dieterly; Soonbum Kwon; Jinho Park; Fanfei Meng; Hytham H Gadalla; Maria Jose Cadena; L Tiffany Lyle; Yoon Yeo
Journal:  ACS Nano       Date:  2021-03-01       Impact factor: 15.881

Review 4.  Immune evasion pathways and the design of dendritic cell-based cancer vaccines.

Authors:  Brent A Hanks
Journal:  Discov Med       Date:  2016-02       Impact factor: 2.970

Review 5.  RNAi therapeutic strategies for acute respiratory distress syndrome.

Authors:  Melissa L Jagrosse; David A Dean; Arshad Rahman; Bradley L Nilsson
Journal:  Transl Res       Date:  2019-07-27       Impact factor: 7.012

Review 6.  RNA interference for improving the outcome of islet transplantation.

Authors:  Feng Li; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2010-12-13       Impact factor: 15.470

Review 7.  Tolerogenic dendritic cells: all present and correct?

Authors:  A W Thomson
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

Review 8.  Phage protein-targeted cancer nanomedicines.

Authors:  V A Petrenko; P K Jayanna
Journal:  FEBS Lett       Date:  2013-11-20       Impact factor: 4.124

Review 9.  Gene and virotherapy for hematological malignancies.

Authors:  Evidio Domingo-Musibay; Masato Yamamoto
Journal:  Int J Hematol       Date:  2016-06-11       Impact factor: 2.490

10.  RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis.

Authors:  Xiufen Zheng; Motohiko Suzuki; Xusheng Zhang; Thomas E Ichim; Fei Zhu; Hong Ling; Aminah Shunnar; Michael H Wang; Bertha Garcia; Robert D Inman; Wei-Ping Min
Journal:  Arthritis Res Ther       Date:  2010-01-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.